|
| Human Complement Component C1s Protein (LTP10012) |
|
| LTP10012 |
|
| 100ug |
|
|
$473 In stock |
| Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). |
| Recombinant Human Complement Component C1s Protein is expressed from Expi293 with His tag at the C-terminal. It contains Glu16-Asp688. |
|
| Complement Component C1s |
|
| Human |
|
| P09871 |
|
| Glu16-Asp688 |
|
| The protein has a predicted MW of 75.98 kDa. Due to enzyme lysis glycosylation, the protein migrates to 55-60 kDa (light chain), 32-35 kDa (heavy chain) and 76-96 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-His |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
